drug · protein
efgartigimod alfa
pre_registrationupdated 6mo agoby $ARGX ARGENX SE🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 3Protein drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 14 investigational indications.
targets
IgG receptor FcRn large subunit p51
all catalysts(0)
nothing on the calendar yet
Trials studying efgartigimod alfa
News(10)
- Deaths, failed trials and other recent setbacks in the autoimmune spaceNovartis, Bristol Myers Squibb, argenx and more have recently been hit with challenges as they attempt to advance assets targeting autoimmune diseases, with some programs being axed entirely while…biospace · 1d ago
- Argenx is spending billions to push beyond VyvgartSix months into her term as CEO of rare disease drugmaker argenx, Karen Massey has overseen two acquisitions worth a combined potential of about $3.4 billion as the company seeks to build a broader…endpoints · 3d ago
- Argenx to buy peptide platform in potentially billion-dollar dealFor $550 million up front, Argenx will take control of Unnatural Products’ “macrocyclic peptide” technology and direct it to develop oral, durable medicines for serious immune-mediated diseases.biopharma_dive · 7d ago
- Argenx inks $1.15B Unnatural Products buyout to expand in oral peptidesArgenx has struck a deal to acquire Unnatural Products for $550 million upfront, snapping up the Merck & Co.- and Novartis-partnered biotech to add oral peptide capabilities.fiercebiotech · 8d ago
- STAT+: Pharmalittle: We’re reading about a setback for Argenx, Lilly suits over copycat versions of an obesity drug, and moreThe FDA flagged a potential safety signal after four patient deaths in a trial testing a schizophrenia drug, Argenx faces an unusual setback, and more pharma news.stat · 1mo ago
- Argenx falls as Sjögren’s setback offsets celiac drug progressA monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ‘blockbuster expansion opportunity’ for Vyvgart.biopharma_dive · 1mo ago
- Argenx shutters Sjogren's study, losing blockbuster expansion opportunity for VyvgartArgenx shares have fallen more than 13% after the surprise futility finding, which overshadowed a mid-stage celiac disease win for a separate asset acquired in the company’s $2.2 billion Forte Bios…biospace · 1mo ago
- STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune diseaseArgenx said its blockbuster drug Vyvgart didn’t outperform placebo in a Phase 3 trial of patients with Sjögren's disease, a chronic autoimmune disorder.stat · 1mo ago
- Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal runA phase 2 celiac disease trial of argenx’s FB102 has hit its primary endpoint, delivering a boost to a drug candidate that the biotech acquired in its $2.2 billion takeover of Forte Biosciences.fiercebiotech · 1mo ago
- Big Pharma-backed Nuvig halts development of lead fusion protein in rare autoimmune diseaseBig Pharma-backed Nuvig Therapeutics has halted one of the two trials for its sole clinical asset after determining the program wouldn’t be able to advance quickly enough.fiercebiotech · 1mo ago
Data sources
last refreshed 18m ago
Found something off?
comments(0)
5-min edit window · permanent after that